Strava Healthcare makes artesunate 100 mg + amodiaquine 270 mg fixed-dose combination tablets for export markets, NGO procurement, and malaria control programmes.
This combination is one of the WHO-recommended artemisinin-based combination therapies (ACTs) for uncomplicated Plasmodium falciparum malaria. The way it works is fairly logical once you understand what each drug does: artesunate hits fast and clears the bulk of the parasite load within the first day or two. Amodiaquine is slower but stays in the system long enough to clear what artesunate leaves behind. Together they reduce transmission, cut the risk of the artemisinin component developing resistance, and deliver a complete three-day treatment in a fixed-dose tablet which in field conditions, where counting out separate drugs reliably is genuinely difficult, is not a small thing.
Artesunate 100mg + Amodiaquine 270mg Tablet are renowned and demanding in Nigeria, Democratic Republic of the Congo, Uganda, Tanzania, Ghana, Kenya, Ethiopia, Mozambique and also in Nigeria, Cameroon, Senegal, Ivory Coast and Mali.
Indications
- Uncomplicated Plasmodium falciparum malaria — first-line in sub-Saharan Africa per WHO guidance
- Mixed Plasmodium infections where falciparum is present
- Malaria in areas with chloroquine resistance
Dosing and Treatment
Three-day course, weight-based dosing. Standard tablets are designed for adults weighing 36 kg and above. Paediatric weight-banded formulations with lower artesunate and amodiaquine doses are available for children — specify at enquiry. Tablets should be taken at the same time each day across all three days.
For B2B and Pharma Partners
- Contract manufacturing for ACT programmes and export supply
- Supply to NGOs, government malaria control programmes, and institutional procurement
- GMP documentation, dossier support, and COPP available
- WHO prequalification-compatible manufacturing standards
Product Specifications
| Parameter | Details |
|---|---|
| Active Ingredient | Artesunate 100 mg + Amodiaquine hydrochloride 270 mg |
| Dosage Form | Film-coated tablet |
| Indication | Uncomplicated Plasmodium falciparum malaria |
| Treatment Duration | 3-day course |
| Packaging | Blister strips — 3 tablets per strip; bulk cartons for institutional supply |
| Storage | Below 30°C, protected from moisture and light |
| Shelf Life | 24 months |
| Manufacturer | Strava Healthcare Private Limited |
Frequently Asked Questions
Artesunate’s half-life is very short. It clears parasites fast, but blood levels drop before the infection is fully eliminated which means monotherapy leaves survivors, and survivors under drug pressure are exactly how resistance develops. That’s the same mechanism that made chloroquine fail across sub-Saharan Africa over decades of monotherapy use. Amodiaquine stays in the system long enough to finish the job and protect the artemisinin from that selective pressure. The combination isn’t just more effective it’s deliberately structured to slow resistance.
First trimester is where it gets complicated. WHO guidance generally prefers quinine in the first trimester, where the theoretical embryotoxicity risk from artemisinins is considered less acceptable given that the pregnancy is most vulnerable. In the second and third trimesters, artesunate-amodiaquine is used — untreated falciparum malaria in pregnancy carries real risk of maternal mortality, severe anaemia, and low birth weight, and that risk typically outweighs the theoretical foetal concern. It’s a clinical judgment call, not a blanket contraindication.
Yes. We supply to malaria-endemic markets and institutional programmes. GMP certificates, batch documentation, and certificates of analysis are standard. Dossier support for import registration and WHO prequalification-compatible documentation are available on request.